Anjali Singh

Domestic two-wheeler wholesales likely to grow 6-9% in FY26: Icra

Wholesales jump 19 per cent in November even as retail sales soften

Cipla to exclusively market and distribute five Pfizer brands in India

Cipla will exclusively market five Pfizer brands in India, adding ₹400-430 crore of established acute therapies to its portfolio without manufacturing risk

Sun Pharma shares slip 3% after US FDA flags Baska manufacturing facility

Sun Pharma's Baska plant in Gujarat receives OAI status from the US FDA after inspection, adding near-term regulatory uncertainty but not impacting current US supplies

Nissan teases 7-seater B-MPV 'Gravite', eyes India comeback from 2026

Scheduled for launch in early 2026, the Gravite will be locally manufactured at Renault-Nissan's Chennai plant and is the first model under Nissan's refreshed India strategy

Tata Motors' Sierra clocks 70,000 bookings on opening day of sales

Tata Motors said the new-generation Sierra logged 70,000 confirmed bookings in 24 hours, with deliveries set from January 15, 2026, and prices ranging from Rs 11.49 lakh

Premium bike sales rise 4% despite GST hike for 350 cc-plus models

Sales volumes rose 7.2 per cent year-on-year in October 2025 to 19,555 units, before moderating by 1.4 per cent in November to 10,396 units

Carmakers gearing up to hit refresh button as facelifts take priority

Planning mid-cycle facelifts over new launches

'India-Sweden economic corridor positioned for robust expansion'

This optimistic outlook builds on the fact that Swedish companies invested a total of $2.5 bn in India over the last six years, highlighting the expanding economic corridor between the two nations

Auto industry logs best Nov sales; PV dispatches surge 19%: SIAM

Sector optimistic that 'supportive policy reforms' will continue, says group

Mercedes-Benz India to hike prices by up to 2%, effective January 1

The company said the euro-INR exchange rate has stayed above the Rs 100 mark through 2025, well above historical averages, significantly raising its cost base

As rupee wobbles and costs surge, car firms gear up for new-year price rise

forex pressures, rising commodity prices, rural demand uncertainty to push prices up

Zydus and Formycon ink licensing agreement for biosimilar in US, Canada

Zydus will commercialise FYB206 in North America, while Formycon will lead development, regulatory filings and supply, with a US FDA filing expected soon

ATGC Biotech, Israel's Luxembourg Industries form Semiophore crop-tech JV

The JV plans to commercialise 18 semiochemical and pheromone technologies developed by ATGC Biotech in multiple international markets, including Israel, Brazil, Australia and countries in Africa

Past gets a second drive as Indian carmakers revive legacy nameplates

Indian automakers are reviving legacy nameplates to leverage brand recall and stand out in a crowded market, as classic badges like Sierra, Safari, Baleno and Scorpio return to attract buyers

ASG Eye Hospital to invest ₹2,000 crore, scale to 600-700 centres

ASG Eye Hospital will invest Rs 2,000 crore to expand from 175-plus centres to 600-700 by 2030, using acquisitions, new hospitals and district centres, backed by investors

NephroPlus plans global scale-up ahead of IPO amid rising CKD burden

India's largest dialysis provider plans to expand clinics at home and abroad ahead of its December 10 IPO, betting on rising CKD burden and demand for accessible dialysis care

Corona Remedies bets on female hormone complex generics ahead of IPO

Corona Remedies is pushing into female hormone complex generics to expand beyond India, as its Rs 655.3-crore OFS IPO opens December 8, with a new hormone plant and a stake in La Chandra Pharma Labs

Claims vs reality: Dust doesn't settle on Mumbai's clean-air drive

- On paper, machines are deployed daily but residents, workers and vendors say dust still hangs heavy in the air

Mumbai gasps under a blanket of smog, BMC swings into pollution-war mode

The civic body said Mumbai's air quality has improved since November 26, supported by ongoing measures and wind speeds rising to 10-18 kilometres per hour

Lupin gets US FDA nod for its first biosimilar drug Pegfilgrastim

The product, a biosimilar to Amgen's popular drug Neulasta, will be manufactured at Lupin's biotech facility in Pune